Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Miami Jewish Health / Stein Gerontological Institute
mi
from
Miami, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health / Stein Gerontological Institute
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Medical Research Group of Central Florida
mi
from
Orange City, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Medical Research Group of Central Florida
mi
from
Orange City, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Bioclinica Research
mi
from
Orlando, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Bioclinica Research
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Stedman Clinical Trials
mi
from
Tampa, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Neuroscience Institute
mi
from
Elk Grove Village, IL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Neuroscience Institute
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
The Cognitive Research Center of New Jersey
mi
from
Springfield, NJ
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
The Cognitive Research Center of New Jersey
mi
from
Springfield, NJ
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Syrentis Clinical Research
mi
from
Santa Ana, CA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Syrentis Clinical Research
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Medical Research and Health Education Foundation, Inc.
mi
from
Columbus, GA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Medical Research and Health Education Foundation, Inc.
mi
from
Columbus, GA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Insight Clinical Trials
mi
from
Shaker Heights, OH
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Insight Clinical Trials
mi
from
Shaker Heights, OH
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Southern California Research, LLC
mi
from
Simi Valley, CA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Southern California Research, LLC
mi
from
Simi Valley, CA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
MD Clinical
mi
from
Hallandale Beach, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Phoenix Medical Research
mi
from
Miami, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Phoenix Medical Research
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Miami Dade Medical Research Institute
mi
from
Miami, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Miami Dade Medical Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Anchor Neuroscience
mi
from
Pensacola, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Anchor Neuroscience
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Disease Center
mi
from
Quincy, MA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Disease Center
mi
from
Quincy, MA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
The Burke Rehabilitation Hospital
mi
from
White Plains, NY
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
The Burke Rehabilitation Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
Memory Health Center at Summit Research Network
mi
from
Portland, OR
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Memory Health Center at Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
OCTA in Mild Cognitive Impairment and Alzheimer's Disease
Evaluating the Retinal Microvasculature in Mild Cognitive Impairment and Alzheimer's Disease Using Optical Coherence Tomography Angiography
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
OCTA in Mild Cognitive Impairment and Alzheimer's Disease
Evaluating the Retinal Microvasculature in Mild Cognitive Impairment and Alzheimer's Disease Using Optical Coherence Tomography Angiography
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Partners at Meals - Respite Care and Home (PAM)
Mealtime Partnerships for People With Dementia in Respite Centers and at Home
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Partners at Meals - Respite Care and Home (PAM)
Mealtime Partnerships for People With Dementia in Respite Centers and at Home
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients
Determining if a Personalized Mito Food Plan Diet and Cellular Repair Therapy Based on Individual Physiological and Cellular Comprehensive Body Assessments in Patients With Alzheimer's Disease Decreases Inflammation and Oxidative Stress
Status: Enrolling
Updated:  12/31/1969
Perseverance Research Center
mi
from
Scottsdale, AZ
Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients
Determining if a Personalized Mito Food Plan Diet and Cellular Repair Therapy Based on Individual Physiological and Cellular Comprehensive Body Assessments in Patients With Alzheimer's Disease Decreases Inflammation and Oxidative Stress
Status: Enrolling
Updated: 12/31/1969
Perseverance Research Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
The Depression in Alzheimer's Disease Study (DIADS)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
The Depression in Alzheimer's Disease Study (DIADS)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Status: Enrolling
Updated:  12/31/1969
Durham VA
mi
from
Durham, NC
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Status: Enrolling
Updated: 12/31/1969
Durham VA
mi
from
Durham, NC
Click here to add this to my saved trials
Music Therapy for Persons With Dementia
Music Therapy for Persons With Dementia: A Randomized Clinical Crossover Trial
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Music Therapy for Persons With Dementia
Music Therapy for Persons With Dementia: A Randomized Clinical Crossover Trial
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Status: Enrolling
Updated:  12/31/1969
Center for Alzheimer's Care, Imaging and Research
mi
from
Salt Lake City, UT
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Status: Enrolling
Updated: 12/31/1969
Center for Alzheimer's Care, Imaging and Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
New Haven, CT
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Howard University
mi
from
Washington,
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Howard University
mi
from
Washington,
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Boston University School of Medicine
mi
from
Boston, MA
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Mobile, AL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Northport, AL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Northport, AL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Little Rock, AR
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Oceanside, CA
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
San Diego, CA
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Santa Rosa, CA
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Pueblo, CO
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Pueblo, CO
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Hockessin, DE
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Hockessin, DE
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Bradenton, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Brooksville, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Brooksville, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Clearwater, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Daytona Beach, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Destin, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Destin, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Fort Myers, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Fort Walton Beach, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Fort Walton Beach, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Fruitland Park, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Fruitland Park, FL
Click here to add this to my saved trials